...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: What's going on with the Phase 2 ZEN-3694 mCRPC trial?

ZEN-3694/Enzalutamide/mCRPC trial listing was updated this week. Estimated completion now October 2019.

https://clinicaltrials.gov/ct2/show/NCT02711956

 

Share
New Message
Please login to post a reply